Helus Pharma Inc.
HELP | NASDAQ
$10.60
-$0.11 (-1.03%)
At close: Oct 30, 2026, 4:00 PM ET
$10.77
+$0.17 (+1.60%)
Pre-market:
Nov 2, 2026, 7:09 AM ET
Company Profile
Cybin Inc. functions as a biopharmaceutical company currently in its clinical development phase, concentrating on the advancement of novel therapeutic agents derived from psychedelic compounds. Its research pipeline includes CYB003, a deuterated psilocybin analog under investigation for major depressive disorder, and CYB004, a deuterated DMT compound being developed to address generalized anxiety disorder.
Key Executives
| Name | Position |
|---|---|
| Michael I. Halstead | CEO & Director |
| Aaron Bartlone | Chief Operating Officer |
| Gabriel Fahel | Chief Legal Officer & Corporate Secretary |
| Greg Cavers | Chief Financial Officer |
| Regina Donohue | Chief People Officer |
| Alex L. Nivorozhkin | Chief Scientific Officer |
| Amir Inamdar FFPM MBBS | Chief Medical Officer |
| Eric So | Co-Founder, President & Executive Chairman |
| Geoff Varty | Senior Vice President of Research & Pre-Clinical Development |
| George Tziras | Chief Business Officer |
| John Kanakis | Co-Founder |
| Lori Challenger | Chief Compliance, Ethics & Administrative Officer |
| Paul Glavine | Co-Founder, Chief Growth Officer & Director |
| Sara Brittany Somerset | Chief Communications Officers |
Helus Pharma Inc.
| Country | Canada |
| IPO Date | Sep 13, 2019 |
| Industry | Medical - Pharmaceuticals |
| Sector | Healthcare |
| Employees | 100 |
| CEO | Michael I. Halstead |
Contact Details
100 King Street West, Suite 5600 Toronto,
ON M5X 1C9 Canada
Stock Details
| Ticker Symbol | HELP |
| Exchange | NASDAQ |
| Fiscal Year | n/a |
| Reporting Currency | USD |
| CIK Code | 0001833141 |
| CUSIP Number | 423492107 |
| ISIN Number | CA4234921076 |
| SIC Code | n/a |
Add to Watchlist
Select watchlists to add or remove HELP